Skip to main content

Table 2 Biomarkers of cellular and plasma hypercoagulability in patients and controls

From: Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability

 

Control group (n = 30) (95% CI)

Breast cancer group (n = 62)

 

All patients (n = 62) (95% CI)

Local stage (n = 13) (95% CI)

Regional stage (n = 29) (95% CI)

Metastatic stage (n = 20) (95% CI)

MRI (nM/min)

109 ± 33 (96,5–121)

159 ± 47** (139–168)

172 ± 55§* (138–205)

146 ± 56§ (122–168)

162 ± 49** (126–180)

Peak (nM)

288 ± 48 (269–305)

341 ± 65* (323–365

369 ± 75** (323–414)

334 ± 90§§ (301–371)

343 ± 69§ (306–370)

ETP (nM.min)

1498 ± 225 (1413–1581)

1531 ± 337 (1448–1623)

1626 ± 332 (1424–1826)

1499 ± 374 (1366–1656)

1515 ± 285 (1369–1650)

Pd-MP (/μL)

756 ± 429 (650–1100)

10015 ± 8223§§ (7890–12138)

9370 ± 7724 (4702–14038)

7847 ± 6479*** 5334–10359)

13650 ± 9864 (8895–18404)

Pd-MP/PS + (/μL)

695 ± 361 (550–1020)

9698 ± 7931§§ (7649–11746)

9115 ± 7428 (4626–13604)

7570 ± 6241*** (5150–9991)

13231 ± 9512 (8646–17816)

PPL (sec)

72.8 ± 9.9 (59–66)

43,5 ± 10,3 (41–46)

45 ± 10,2 (39–51)

44,3 ± 9,8 (40–48)

41,3 ± 11,3$ (35–47)

D-Dimers (ng/ml)

230 ± 50 (279–340)

1250 ± 1773 (767–1648)

605 ± 499*** (303–907)

1123 ± 1429 (503–1572)

1853 ± 2497 (703–3154)

  1. Values are depicted as mean ± sd. The 95% Confidence Interval of the mean (95% CI) is also shown.
  2. *p = 0,001 versus controls, **p < 0,001 versus controls, §p < 0,01 versus controls, §§p < 0,05 versus controls, ***p < 0,05 versus metastatic stage, $p < 0,05 versus local stage.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us